Loading quotes...

Forecast

The analysts' average price target is €54.29 (+40.65%). The median is €53.69 (+39.09%).

Buy	9
Hold	5
Sell	0

News Go to news feed

Vericel reaches new 52-week high at $48.41

Vericel shares rose to a 52-week high of $48.41, bringing the market capitalization to about $2.44 billion. InvestingPro rates the stock as undervalued at the current level. Vericel reported robust Q1 2026 results with an EPS of -$0.12 (better than expected) and revenue of $68.4 million, drawing analyst attention and boosting investor sentiment. » More on de.investing.com
Vericel posts 20% revenue growth as Soleus adds $63 million stake

Soleus Capital disclosed a purchase of 1,785,079 Vericel shares in Q1, an estimated $63.4 million trade that leaves Vericel representing 3.32% of Soleus's 13F AUM. Vericel reported Q2 revenue of $63.2 million, up 20% year over year, driven by 21% growth in MACI; gross margin expanded to 74% and adjusted EBITDA rose to $13.4 million. The company ended the quarter with about $164 million in cash and investments, no debt, and received FDA clearance to begin a Phase 3 MACI study for ankle cartilage defects. » More on finance.yahoo.com
Vericel raises full-year guidance after 30% revenue growth in first quarter

Vericel reported Q1 revenue of $68.4 million (+30% year-over-year), beating expectations. Growth was driven mainly by MACI ($56.4 million, +22%) and burns care ($12.0 million, +91%); adjusted EBITDA rose to $9.6 million. The company generated free cash flow of $15.1 million, is debt-free and holds about $211 million in cash and investments. Due to strong momentum, Vericel raised its 2026 revenue guidance to $326–336 million and reaffirmed its margin and EBITDA targets. » More on de.investing.com

Financials

In the last quarter, VERICEL CORP. had revenue of €67.87m and net profit of €1.93m

(EUR)	June 2026	YoY
Revenue	67.87m	26.49%
Gross profit	49.42m	24.96%
Net profit	1.93m	511.98%
EBITDA	5.24m	153.98%

Fundamentals

Metric	Value
Market capitalization	€1.95bn
Number of shares	51.21m
52-week high/low	€44.14 - €25.91
Dividends	No
Beta	1.02
P/E ratio	88.60
PEG ratio	0.36
P/B ratio	5.85
P/S ratio	7.11

Company profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Name	VERICEL CORP.
CEO	Dominick C. Colangelo
Headquarters	Burlington, ma USA
Website	vcel.com
Sector	Consumer Staples
Industry	Food Products
IPO	04/02/1997
Employees	398